Long-term treatment outcome of Castleman’s disease: A real-world experience

Long-term treatment outcome of Castleman’s disease: A real-world experience

BackgroundCastleman disease (CD), classified as unicentric CD (UCD) or multicentric CD (MCD), is a rare non-neoplastic lymphoproliferative disorder of unknown origin. Owing to its rarity, the clinical characteristics, therapeutic modalities, treatment outcomes, and prognostic factors related to UCD...

Full description

Bibliographic Details
Main Authors: Gi-June Min, Young-Woo Jeon, Tong Yoon Kim, Dae Hun Kwag, Jong Hyuk Lee, Joon Yeop Lee, Sung-Soo Park, Silvia Park, Jae-Ho Yoon, Sung-Eun Lee, Byung-Sik Cho, Ki-Seong Eom, Yoo-Jin Kim, Seok Lee, Hee-Je Kim, Chang-Ki Min, Jong Wook Lee, Seok-Goo Cho
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-08-01
Series:Frontiers in Oncology
Subjects:
Castleman disease
interleukin-6
age
splenomegaly
siltuximab
steroids
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2022.974770/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2022.974770/full

Similar Items